CU6 - ASX Charts, page-2112

Hey mate, I think you’ve interpreted slightly different from what the data is showing. The important point, and if you look at the recent abstract, is that for BCr PC very low PSA levels are not showing up as abundantly on current SOC diagnostic scans. If you also correlate this with AT’s recent podcast with Frazis, this is also with brand new high end scanners. An important point to note is that it may not be the bispecific nature of the molecule that is picking up lesions earlier, as Cu64 performed nearly on par with SOC at same day imaging, but that they’re picking up more lesions on next day imaging. This is purely down to the nature of the half life of Cu64.

Anecdotally, AT spoke about a patient(again on the recent podcast) who came to AT noting that there was early PSA rise, with negative SOC diagnostic. He was treated with Ext Beam RT which decreased his PSA levels. This happened twice. AT noted the patient was in the industry, so was on top of everything and was aware that a rising PSA is concerning. When we look at the sensitivity of GA68/F18, the sensitivity sits around 50-60%(from their Cobra trial) and Cu64 was sitting around 90%; a 50% increase in sensitivity over SoC. We can potentially speculate that a lot of the sensitivity that is missed is for very low PSA levels. A very important point for clinicians and which type of diagnostic they would choose.